⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20436779 | 1.00 | — | — | |
| SCHEMBL10042436 | 0.97 | ANPEP (0.32) | — | |
| SCHEMBL23425489 | 0.94 | ANPEP (0.31) | — | |
| SCHEMBL24282818 | 0.94 | ANPEP (0.31) | — | |
| SCHEMBL18746362 | 0.94 | — | — | |
| SCHEMBL12180002 | 0.89 | — | — | |
| SCHEMBL18745535 | 0.89 | — | — | |
| SCHEMBL18745493 | 0.89 | TAS1R3 (0.32) | — | |
| SCHEMBL18389166 | 0.88 | ANPEP (0.31) | — | |
| SCHEMBL87230 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306538-A2 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | Sarepta Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3297649-B1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SAREPTA THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-05 | — | — | US | disclosed |
| US-20230310625-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-10-05 | — | — | US | disclosed |
| US-20230220158-A1 | IONOMERS WITH MACROCYCLIC MOIETIES FOR ION CONDUCTIVITY AND PERMSELECTIVITY | NATIONAL SCIENCE FOUNDATION | 2023-07-13 | — | — | US | disclosed |
| US-20230220158-A1 | IONOMERS WITH MACROCYCLIC MOIETIES FOR ION CONDUCTIVITY AND PERMSELECTIVITY | NATIONAL SCIENCE FOUNDATION | 2023-07-13 | — | — | US | disclosed |
| WO-2023107674-A2 | STAPLED PEPTIDE-ANTIBODY CONJUGATES (SPACS) AND USES THEREOF | LYTICA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11672871-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672871-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220072143-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-03-10 | — | — | US | disclosed |
| US-20210290772-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2021150867-A1 | DESIGNING ANTISENSE OLIGONUCLEOTIDE DELIVERY PEPTIDES BY INTERPRETABLE MACHINE LEARNING | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| US-20200254109-A1 | Peptide Oligonucleotide Conjugates | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-13 | — | — | US | disclosed |
| US-20200237922-A1 | BICYCLIC PEPTIDE OLIGONUCLEOTIDE CONJUGATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-07-30 | — | — | US | disclosed |
| US-10675356-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| WO-2020028254-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20180214567-A1 | Peptide Oligonucleotide Conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180214567-A1 | Peptide Oligonucleotide Conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-08-02 | — | — | US | disclosed |